PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data PolyPid NASDAQ: PYPD is approa...
Topics
PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data PolyPid NASDAQ: PYPD is approaching a November 28 PDUFA date for D-PLEX100, its lead product candidate for preventing surgical site infections in patients undergoing colorectal surgery, Chief Executive Officer Dikla Czaczkes Akselbrad said during the Lytham Partners Fall 2026 Investor Conference.
Related QATS news
- Microsoft Is the ‘Adult in Charge' on Fears Over AI Security. Stock Gets Upgraded to Buy. Fears ove...
- I'm Betting On The S&P 500 Hitting 10,000 I'm betting on the S&P 500 hitting 10,000, optimistically...
- Lamb Weston (LW) Soars 5.9%: Is Further Upside Left in the Stock? Lamb Weston (LW) was a big mover ...
- FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) Highlights FFAI Weekly Investor Update: FF EAI Robotics...